The Latest Analyst Ratings for Editas Medicine
Portfolio Pulse from Benzinga Insights
Editas Medicine (NASDAQ:EDIT) has received 4 analyst ratings in the last quarter, with 3 being bullish, 1 indifferent, and none bearish. The average price target is $14.0, representing an implied upside from the current price of $9.84. The price target has increased by 16.67% over the past month. Analyst ratings are based on information from company activities and financials, and while they provide guidance, they are subjective opinions.
December 12, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Editas Medicine has received mostly bullish ratings from analysts, with a significant implied upside based on the average price target of $14 compared to its current price.
The positive analyst ratings and the recent increase in the price target suggest a bullish sentiment, which could lead to a short-term increase in the stock price. However, as analyst ratings are subjective, they should be considered as part of a broader investment strategy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100